Replimune stock.
Contact Email: [email protected]. Contact Phone Number: +1 (781) 222 9570. Replimune’s investigational products and their uses are investigational, have not been proven to be safe and have not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authority.
Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 11.71 +0.53 (+4.74%) At close: 04:00PM EST 11.71 0.00 (0.00%) After hours: 04:20PM EST 1d 5d 1m...6.68. +0.68. +11.33%. Get Replimune Group Inc (REPL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Replimune Group, Inc. announced that members from the Replimune management team ... shares of its common stock at a public offering price of $23.50 per share.Replimune | Stock Quote & Chart Investors & Media Overview Events and Presentations Press Releases Corporate Governance Financials & Filings Stock Information Publications Email Alerts Investor Contact Select Page Stock Quote & Chart Stock Quote & Chart Historical Price Analyst Coverage Change Volume Today's Open Previous Close Today's High
November 29, 2023. $11.32. 786,621. 1:1. $11.67. $11.95. $11.26. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown.Using Order Flow and Market Profile to Trade Stocks. 0. 1. Love in every #TradingView. 50M+. Traders and investors use our platform.They pay benefits on behalf of the employees. Healthcare and life insurance without premiums. Good benefits, could use HSA. Great benefits, growing company, plenty to learn. Free health care is very good. Good stock options, and retirement matching.
Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.Jul 9, 2023 · Replimune's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Find out why REPL stock is a Buy.
WOBURN, Mass.Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic ...6 brokers have issued 12-month price objectives for Replimune Group's shares. Their REPL share price targets range from $34.00 to $70.00. On average, they anticipate the company's share price to reach $51.33 in the next year. This suggests a possible upside of 353.5% from the stock's current price.Replimune Group Stock (NASDAQ: REPL) stock price, news, charts, stock research, profile.Investors are always looking for stocks that are poised to beat at earnings season and Replimune REPL may be one such company. The firm has earnings coming up pretty soon, and events are shaping ...
Replimune is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. RPx therapies are engineered using a proprietary HSV-1 strain and immune activating transgenes to maximize T cell stimulation and systemic immune activation. RP1 is designed to treat more immune ...
Replimune Group stock price forecast: $52; Market Cap: 686.26M, Enterprise value: 781.76M, P/E: -5.9, PEG ratio: 0.20, EPS: -3.1, Revenue: N/A, ...
Replimune Group, Inc. Common Stock (REPL) Earnings Report Date | Nasdaq. Created with Sketch. Zacks earnings numbers are reported on a BNRI (Before Non Recurring Items) basis and include stock ...Mar 30, 2022 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ... Dec 4, 2023 · Replimune Group Stock Performance. Shares of REPL stock opened at $11.71 on Monday. The company has a market cap of $691.58 million, a price-to-earnings ratio of -3.80 and a beta of 1.46. The stock has a 50 day simple moving average of $13.43 and a 200-day simple moving average of $18.08. Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...Replimune | Stock Quote & Chart Investors & Media Overview Events and Presentations Press Releases Corporate Governance Financials & Filings Stock Information Publications Email Alerts Investor Contact Select Page Stock Quote & Chart Stock Quote & Chart Historical Price Analyst Coverage Change Volume Today's Open Previous Close Today's High
A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Get the latest Replimune Group Inc. (REPL) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Report of unscheduled material events or corporate event. 8-K. 0001104659-23-115027.pdf. 0001104659-23-115027.rtf. 0001104659-23-115027.xls. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML. Nov 07, 2023. Quarterly report which provides a continuing view of a company's financial position. 10-Q.
Replimune Group Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-3.531 per share for the current fiscal year. Replimune Group Inc does not currently pay a dividend.
Replimune's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Find out why REPL stock is a Buy.Rhumbline Advisers cut its position in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 5.2% in the second quarter, according to the …Stock analysis for Replimune Group Inc (REPL:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.14 Des 2022 ... in its approximately $260 million public offering of 6,810,658 shares of common stock, inclusive of the underwriters' option to purchase ...View 13F filing holders of Replimune Group Inc. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers. ... *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page*** Elevate your investments Try it for free. We give you the access and tools ...Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is ...Replimune is a rapidly growing company, which is exciting to be a part of. There are bonuses, stock options and company outings which make it an appealing company to work for. The company buys lunch at least once a week. Cons. There’s not a lot of stability in day-to-day, week-to-week operations.
Replimune story: Exercise or conversion by Pamela Esposito of 25800 shares of Replimune subject to Rule 16b 3 and other headlines for Replimune Group
Nov 13, 2023 · Replimune Group Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-3.531 per share for the current fiscal year. Replimune Group Inc does not currently pay a dividend.
Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) saw some unusual options trading on Friday. Traders purchased 5,463 call options on the stock. This is an increase of approximately 87% ...WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the grant of inducement equity awards to Emily Hill, the Company’s newly appointed Chief Financial Officer.WOBURN, Mass. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present. July 31, 2023. Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Get the latest Replimune Group Inc. (REPL) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Replimune Group, Inc. Common Stock (REPL) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is...Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsReplimune’s tumor-directed oncolytic immunotherapies have the potential to redefine the cancer treatment paradigm. Replimune’s approach brings together multiple mechanisms of action to destroy the tumor, ignite an anti-cancer response, and generate long-lived immune activity. The ultimate aim is to improve outcomes for patients with cancer.
Nov 3, 2022 · About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death ... Replimune Group - REPL - Stock Price Today - Zacks Replimune Group (REPL) (Delayed Data from NSDQ) $10.40 USD +0.08 (0.78%) Updated Nov 17, 2023 …Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha's top analysts: exclusive research and insights from bulls and bears.Instagram:https://instagram. what's the value of a 1921 morgan silver dollarpenny stock appsjoby stock price prediction 2025forex trading brokers australia Barclays has chosen Biomea Fusion (BMEA), Replimune (REPL), Syndax (SNDX) and Iovance (IOVA) as its top picks in the small and mid-cap oncology space for the latter half of 2023.Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get... sofi stckeemv Find real-time REPL - Replimune Group Inc stock quotes, company profile, news and forecasts from CNN Business.Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. stock splits announced BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its common stock at a public offering price of …Dec 7, 2022 · In addition, Replimune intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock from Replimune at the public offering price ...